3TR

Taxonomy, Treatment, Targets and Remission
logo del progetto 3TR
Classificazione: 
internazionali
Programma: 
Altri programmi dell'Unione Europea
Call / Bando: 
H2020-JTI-IMI2-2018-14-01
Settore ERC: 
Life Sciences
Ruolo Unict: 
Partner
Durata del progetto in mesi: 
84
Data inizio: 
Domenica, 1 Settembre 2019
Data fine: 
Lunedì, 31 Agosto 2026
Costo totale: 
€ 80.546,00
Quota Unict: 
€ 150.000,00
Coordinatore: 
Fundación Publica Andaluza Progreso y Salud (FPS) - Spain
Responsabile/i per Unict: 
Francesco Pappalardo
Dipartimenti e strutture coinvolte: 
Department of Drug Sciences
Altri partner: 

The University of Manchester (MAN) United Kingdom - Christian-Albrechts-Universitaet zu Kiel (CAU) Germany - University of Leicester (ULEIC) United Kingdom - Eurice European Research and Project Office GmbH (EURICE) Germany - Fundació Centre de Regulació Genòmica (CRG) Spain - European Respiratory Society (ERS) Switzerland - Fondazione Irccs Ca' Granda IRCCS - Ospedale Maggiore Policlinico (IRCCS) Italy - Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC) Netherlands - Academisch Ziekenhuis Groningen (UMCG) the Netherlands - Alacris Theranostics GmbH (ALACRIS) Germany - Atrys Health SA (ATRYS) Spain - Azienda Ospedaliera di Padova (AOPD) Italy - Azienda Ospedaliera – Universitaria Anna Meyer (AOUMEYER) Italy - Universitair Ziekenhuis Belgium - Region Hovedstaden, CRU, Health Research & Innovation Denmark - Centre Hospitalier Régional Universitaire (CHRU Nancy) France - University of Glasgow (UGLA) United Kingdom - Charité - Universitaetsmedizin Berlin (CHARITE) Germany - Agencia Estatal Consejo Superior de Investigaciones Científicas M.P. (CSIC) Spain - Consorci Institut D'investigacions Biomediques August Pi I Sunyer (IDIBAPS) Spain - Consorcio Centro de Investigacion biomedica en Red M.P. (CIBER) Spain - Deutsches Rheuma-Forschungszentrum Berlin (DRFZ) Germany - European Federation of Asthma & Allergy Associations Ideell Forenning (E.F.A.) Belgium - European Lung Foundation (ELF) United Kingdom - Genos Doo Za Vjestacenjei Analizu (GENOS) Croatia - Imperial College of Science Technology and Medicine (IMPERIAL) United Kingdom - Institut National de la Sante et de la Recherche Medicale (INSERM) France - Instituto de Medicina Molecular Joao Lobo Antunes (iMM) Portugal - Karolinska Institutet (KI) Sweden - Lupus Europe (LUPUS EUROPE) United Kingdom - Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (MPI-MG) Germany - Medizinische Hochschule Hannover (MHH) Germany - Örebro University (ORU) Sweden - Owlstone Medical Limited (OWLSTONE) United Kingdom - Philipps Universität Marburg (UMR) Germany - Queen Mary University of London (QMUL), whose administrative offices are at 327 Mile end road, London, E1 4NS, United Kingdom - Servicio Andaluz de Salud (SAS) Spain - Servicio Madrileno de Salud (SERMAS) Spain - SIP Service (SIP Service) Italy - Société de Pneumologie de Langue Française (SPLF) France - Stichting VUmc (VUMC) Netherlands - Technische Universitaet Dresden (TUD) Germany - The Chancellor Masters and Scholars of the University of Cambridge (UCAM) United Kingdom - The Queen’s University of Belfast (QUB) United Kingdom - Università degli Studi del Piemonte Orientale Amedeo Avogadro (UNIPMN) Italy - Università degli Studi di Cagliari (UNICA) Italy - Università Degli Studi di Genova (UNIGE) Italy - Università di Pisa (UNIPI) Italy - Universitat Basel (UNIBAS) Switzerland - Cliniques Universitaires Saint-Luc (CUSL) Belgium - Université de Bretagne Occidentale (UBO) France - Universiteit Hasselt (UHASSELT) Belgium - Universitetet i Bergen (UiB) Norway - University College Dublin, National University of Ireland (NUID UCD) Ireland - University College London (UCL) United Kingdom - Katholieke Universiteit Leuven (KU Leuven) Belgium - University of Southampton (SOTON) United Kingdom - Universytet Medyczny W Lodzi (LODZ) Poland - VIB vzw (VIB) Belgium - Sanofi-Aventis Deutschland GmbH (SANOFI) Germany - Janssen Pharmaceutica NV (JANSSEN) Belgium - Takeda Development Centre Europe Ltd. (TAKEDA) United Kingdom - Astrazeneca AB (MEDIMMUNE) Sweden - Glaxosmithkline Research and Development Ltd. (GSK) United Kingdom - Novartis Pharma AG (NOVARTIS) Switzerland - Pfizer Ltd. (PFIZER) United Kingdom - F. Hoffmann-La Roche AG (ROCHE) Switzerland.

ABSTRACT

3TR is a transdisciplinary consortium that unites experts from different areas of medicine, basic sciences and bioinformatics. Among the 69 partners are academic institutions, SMEs, pharmaceutical companies and patient organisations. They all have teamed up to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. By bringing together and harmonising data from existing academic or industry-sponsored studies 3TR aims to identify novel biomarkers leading to improved patient management and personalised therapy. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a “de novo” observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Since the studies will be at different phases of progression, a “carrousel model” was designed for the input and output of data, which will be continuously analysed, interpreted, and crossvalidated. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression.
he central working objectives are:

  • establish a centralised data and sample management platform;
  • perform comprehensive molecular and clinical characterisation of a prospective patient cohort;
  • establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods;
  • identify sets of predictive biomarkers of response/non-response to therapies;
  • improve the competitiveness of European industry and support development of novel solutions.

3TR will sustain the samples and its knowledge base beyond the project end. The project will challenge and revolutionise the conventional “single disease”-based approach with important implications for future treatment.